Drug details:
Molecular formula: C₂₉H₄₃NO₄S

Standard name: [2,6-di(propan-2-yl)phenyl] N-[2-[2,4,6-tri(propan-2-yl)phenyl]acetyl]sulfamate

Synonyms:

2,6-Diisopropylphenyl (2-(2,4,6-triisopropylphenyl)acetyl)sulfamate [2,6-di(propan-2-yl)phenyl] N-[2-[2,4,6-tri(propan-2-yl)phenyl]acetyl]sulfamate ((2,4,6-Tris(1-methylethyl)phenyl)acetyl)sulfamic acid 2,6-bis(1-methylethyl)phenyl ester Sulfamic acid, N-[2-[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester 2,6-Diisopropylphenyl (2-(2,4,6-triisopropylphenyl)-acetyl)sulfamate N-((2,6-Bis(1-methylethyl)phenoxy)sulfonyl)-2,4,6-tris(1-methylethyl)-benzeneacetamide Avasimibe [USAN] Avasimibe(CI-1011) Avasimibe [USAN:INN] ......

Curated SMILES: CC(C)C1=C(C(=CC=C1)C(C)C)OS(=O)(=O)NC(=O)CC2=C(C=C(C=C2C(C)C)C(C)C)C(C)C

Evidence for compound's anti-virulence activity:

Escherichia
Related VF: TTSS secreted effectors
Target: NleB1
Drug effect: Inhibits the activity of the Citrobacter rodentium NleB, E. coli NleB1, and S. enterica SseK1 enzymes.
Max phase: Preclinical (in vivo)
Publication:
Hasan MK, et al., 2022. Repurposing Avasimibe to Inhibit Bacterial Glycosyltransferases. Pathogens 11(3):370.

Salmonella
Related VF: TTSS-2 secreted effectors
Target: SseK1
Drug effect: Inhibits the activity of the Citrobacter rodentium NleB, E. coli NleB1, and S. enterica SseK1 enzymes.
Max phase: Preclinical (in vivo)
Publication:
Hasan MK, et al., 2022. Repurposing Avasimibe to Inhibit Bacterial Glycosyltransferases. Pathogens 11(3):370.